ERBB2 and breast cancer: Notably, we have uncovered that distinct BC subtypes, namely ERα-positive/PR-positive/HER2-negative and ERα-positive/PR-negative/HER2-positive, exhibit selective sensitivity to the inhibition of these kinases, respectively.